A prospective, multi-center feasibility study, the EnligHTN I trial treated 46 patients whose blood pressure remained resistant despite being on three antihypertensive medications and a diuretic. To be considered for the study, patients were required to have a systolic blood pressure greater than or equal to 160 mmHg (150mmHg for patients with type 2 diabetes).

"Renal denervation represents an important area of research in the management of hypertension for the millions of patients who live with this life-threatening condition," said Dr Frank J Callaghan, president, St Jude Medical Cardiovascular and Ablation Technologies Division. "We are pleased with the rapid and sustained reduction of blood pressure to date and remain committed to advancing the science, technology and clinical evidence surrounding this important new procedure."